Financial impact of new vaccine introduction in Uganda

C. Natasha Hsi, MPH
Emory University / PHRplus
November 17, 2003
APHA
Introduction

▲ USAID/W and USAID/Uganda requested assistance from PHRplus project to support the immunization program in Uganda which received $ and vaccines from GAVI

▲ Global Alliance for Vaccines and Immunizations (GAVI):
  ▲ Strengthen routine immunizations
  ▲ Accelerate introduction of new vaccines in developing countries
Contributions from the Vaccine Fund (GAVI) in Uganda

- Received $ and vaccines in 2001
- Injection safety materials: Auto-disable (AD) syringes ($1,157,000 for 3 years)
- Support funds (US$ 910,000 x 2 years) to strengthen the system and increase coverage
- Addition of two antigens:
  - Hepatitis B (Hep B)
  - *Haemophilus influenzae* type b (hib)
  - Using “pentavalent” presentation: DTP+Hep B+hib ($50 million over 5 years)
Vaccine Fund support for a limited time period

▲ Support for doses available for 5 years
▲ Financial Sustainability Plan is a tool for countries:
  ▲ Assesses the cost and financing of immunizations prior to GAVI
  ▲ Makes projections of costs and financing post-GAVI funding period
  ▲ Develops a strategy for post-GAVI
GAVI definition of financial sustainability

“Although self-sufficiency is the ultimate goal, in the nearer term sustainable financing is the ability of a country to mobilize and efficiently use domestic and supplementary external resources on a reliable basis to achieve current and future target levels of immunization performance”
Cost of routine immunization program prior to introduction of Hepatitis B and Hib vaccines

▲ Fiscal year 2000/01, baseline year, no GAVI funding:
   ▲ Total costs: $4.5 million

▲ Fiscal year 2001/02, first year of GAVI funding (1 month of pentavalent vaccine):
   ▲ Total costs: $6.4 million

▲ Fiscal year 2002/03, first full year with pentavalent vaccine:
   ▲ Total costs: $21.2 million
Funding sources for immunization program

- Other funding sources
- Vaccine Fund
- Government
Cost of immunization program

- Cost of immunization program
- $0
- $5,000,000
- $10,000,000
- $15,000,000
- $20,000,000
- $25,000,000

2000/01 2001/02 2002/03

- Other costs
- Pentavalent vaccine
- Basic antigens

PHRplus
Why is there a $15 million funding gap?

Cost of pentavalent vaccine formulation
- DPT: $0.09/dose
- DPT-Hep B: $1.00/dose
- DPT-Hep B-Hib: $3.45/dose

Population growth
- 3.4%

Increase in coverage
- 58% in 2000 to 77% in 2003 for DPT3
Vaccine cost versus gov’t vaccine allocation by MOH

Vaccine cost as a proportion of GOU health budget
Vaccine allocation as a proportion of GOU health budget
What are the policy implications of the financial impact of the new vaccines in Uganda?

What is realistic for financial sustainability in Uganda?
- Basic antigens
- Injection safety
- Hepatitis B, Hib

Price of pentavalent formulation

Reevaluate the disease burden of Hepatitis B and Hib in Uganda

Evidence-based resource allocation
The PHRplus Project is funded by U.S. Agency for International Development and implemented by:
Abt Associates Inc. and partners, Development Associates, Inc.; Emory University Rollins School of Public Health; Philoxenia International Travel, Inc. Program for Appropriate Technology in Health; SAG Corp.; Social Sectors Development Strategies, Inc.; Training Resources Group; Tulane University School of Public Health and Tropical Medicine; University Research Co., LLC.

URL: http://www.phrplus.org